Suppressing fibrin could help prevent or treat periodontal disease: Study

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-02-21 03:30 GMT   |   Update On 2022-02-21 03:30 GMT

A recent study published in Science, suggests that suppressing abnormal fibrin activity could hold promise for preventing or treating periodontal disease, as well as other inflammatory disorders marked by fibrin buildup, including arthritis and multiple sclerosis. Mucosal barrier sites are continuously exposed to diverse environmental stimuli, and the fine-tuning of mucosal...

Login or Register to read the full article

A recent study published in Science, suggests that suppressing abnormal fibrin activity could hold promise for preventing or treating periodontal disease, as well as other inflammatory disorders marked by fibrin buildup, including arthritis and multiple sclerosis.

Mucosal barrier sites are continuously exposed to diverse environmental stimuli, and the fine-tuning of mucosal tissue–specific immune responses is key to maintaining tissue homeostasis. However, specific mechanisms of mucosal barrier immunity remain to be elucidated. In humans, congenital deficiency in plasminogen—the proenzyme form of the abundant plasma protease plasmin—leads to severe mucosal inflammatory disease with oral (ligneous periodontitis), ocular (ligneous conjunctivitis), lung, vaginal, and gastrointestinal tract involvement, which implicates plasmin in mucosal barrier homeostasis.

Fibrin is the principal physiological target of plasmin, and abnormal inflammatory responses associated with plasminogen deficiency in humans and in animal models have been linked to extravascular fibrin deposition. In the oral cavity, excess extravascular fibrin is hypothesized to underlie severe oral mucosal (gingival) inflammation, supporting bone (periodontal) destruction, and adolescent loss of dentition associated with plasminogen deficiency in humans. Mucosal inflammation surrounding dentition and destruction of underlying bone are also hallmarks of common forms of periodontitis. In this study, we sought to determine the mechanistic link between fibrin deposition and oral mucosal immunopathology.

The results:

Researchers employed an array of genetically engineered mouse models and pharmacological inhibitors, complemented by histological and genetic studies in humans, to probe the association between fibrin deposition and local immunopathology. Consistent with findings in plasminogen-deficient humans, mice lacking plasminogen displayed extravascular fibrin accumulation, gingival inflammation, and periodontal bone loss. Oral immunopathology in plasminogen deficiency was prevented by genetic or pharmacological elimination of the fibrin precursor, fibrinogen, demonstrating the critical role of fibrin in plasminogen deficiency–associated mucosal immunopathology.

Notably, oral immunopathology was significantly reduced in plasminogen-deficient germ-free mice compared with specific pathogen–free mice. This suggests that commensal microbial communities represent a trigger for oral mucosal fibrin deposition and associated immunopathology.

Oral lesions in plasminogen-deficient mice were sites of neutrophil accumulation proximal to fibrin deposits. Notably, plasminogen-deficient mice expressing a mutant fibrin lacking the binding site for the myeloid integrin αMβ2 did not develop periodontal disease, despite featuring unabated gingival fibrin deposition and neutrophil accumulation. Fibrin engagement by αMβ2 promoted neutrophil effector functions, including the production of reactive oxygen species and neutrophil extracellular trap (NET) formation (NETosis). Accordingly, genetic or pharmacological ablation of NETosis reduced periodontal bone destruction in plasminogen-deficient mice. Thus, neutrophil activation, through fibrin-neutrophil engagement, triggered oral mucosal immunopathology. Abrogation of fibrin-neutrophil engagement also reduced age-associated periodontal immunopathology under normal fibrinolytic conditions, which was suggestive of a broader role for this mechanism in non-Mendelian forms of periodontitis. Consistent with this notion, variation in the human PLG gene, which encodes plasminogen, was associated with increased prevalence of common forms of severe periodontal disease in a cohort of Americans of European ancestry.

Thus, they identify fibrin as a critical immune regulator of oral mucosal barrier homeostasis, mediated by the local engagement and activation of neutrophils. These findings provide insights into the role of fibrin in neutrophil activation and oral mucosal immunity under both defective and normal fibrinolysis. Their findings pave the way for the investigation of fibrin-neutrophil engagement as a target for the prevention or treatment of the prevalent human disease periodontitis.

Reference:

Niki M. Moutsopoulos et al. Fibrin is a critical regulator of neutrophil effector function at the oral mucosal barrier. Science, 2021; 374 (6575) DOI: 10.1126/science.abl5450.

https://www.science.org/doi/10.1126/science.abl5450



Tags:    
Article Source : Science

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News